Ad-hoc | 9 June 2000 08:38

Ad hoc-Service: Asclepion-Meditec AG ENGLISH

Ad-hoc Mitteilung übermittelt durch die DGAP. Für den Inhalt der Mitteilung ist allein der Emittent verantwortlich. —————————————————————————— FDA approval for new Asclepion laser New laser technology for the growing aesthetic applications market also approved for sale in USA Hair removal – faster and virtually pain-free Asclepion-Meditec AG yesterday received approval from the American health authority, the FDA, for its new top quality aesthetic applications product. The “MeDioStar” system, which was recently presented at the world’s largest trade fair for aesthetic lasers, the AAD in San Francisco, will be launched onto the rapidly growing cosmetic hair removal market. >>This gives us the opportunity to tap into the potential offered by the world’s largest market, the USA,<< said Bernhard Seitz, CEO of Asclepion. ASAPS, the American Society for Aesthetic Plastic Surgery, is predicting three figure growth for this market. Accordingly, the demand for laser-based cosmetic hair removal is rising sharply. The new MeDioStar makes use of the very latest high-power diode technology which considerably accelerates treatment. In addition, an intelligent cooling system ensures that the procedure itself is virtually pain-free. Seitz believes that the device is so packed with new technical features >>hat it represents a genuine innovation for the new millennium.<< >>The MeDioStar is extremely simple to operate by applying it gently to the skin and triggering the laser using the handset,<< continued Seitz. Jena, 08. Juni 2000 Contact: Asclepion-Meditec AG Investor Relations -Jens Brajer- Pruessingstrasse 41 D-07745 Jena Tel.: (+49) 3641 65-3968 Fax.: (+49) 3641 65-3448 eMail: jb@asclepion.com Ende der Mitteilung